LRIG1 is a novel negative regulator of the Met receptor and opposes met and Her2 synergy

被引:103
作者
Shattuck, David L. [1 ]
Miller, Jamie K. [1 ]
Laederich, Melanie [1 ]
Funes, Melanie [1 ]
Petersen, Heidi [1 ]
Carraway, Kermit L., III [1 ]
Sweeney, Colleen [1 ]
机构
[1] UC Davis Canc Ctr, Sacramento, CA 95817 USA
关键词
D O I
10.1128/MCB.00757-06
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The Met receptor tyrosine kinase regulates a complex array of cellular behaviors collectively known as "invasive growth." While essential for normal development and wound repair, this program is frequently co-opted by tumors to promote their own growth, motility, and invasion. Met is overexpressed in a variety of human tumors, and this aberrant expression correlates with poor patient prognosis. Previous studies indicate that Met receptor levels are governed in part by cbl-mediated ubiquitination and degradation, and uncoupling of Met from cbl-mediated ubiquitination promotes its transforming activity. Here we describe a novel mechanism for Met degradation. We find that the Met receptor interacts with the transmembrane protein LRIG1 independent of hepatocyte growth factor (HGF) stimulation and that LRIG1 destabilizes the Met receptor in a cbl-independent manner. Overexpression of LRIG1 destabilizes endogenous Met receptor in breast cancer cells and impairs their ability to respond to HGF. LRIG1 knockdown increases Met receptor half-life, indicating that it plays an essential role in Met degradation. Finally, LRIG1 opposes Met synergy with the ErbB2/Her2 receptor tyrosine kinase in driving cellular invasion. We conclude that LRIG1 is a novel suppressor of Met function, serving to regulate cellular receptor levels by promoting Met degradation in a ligand- and cbl-independent manner.
引用
收藏
页码:1934 / 1946
页数:13
相关论文
共 66 条
[1]   Met/hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation [J].
Abella, JV ;
Peschard, P ;
Naujokas, MA ;
Lin, T ;
Saucier, C ;
Urbé, S ;
Park, M .
MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (21) :9632-9645
[2]  
Bierne H, 2002, J CELL SCI, V115, P3357
[3]   Met, metastasis, motility and more [J].
Birchmeier, C ;
Birchmeier, W ;
Gherardi, E ;
Vande Woude, GF .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (12) :915-925
[4]   ESSENTIAL ROLE FOR THE C-MET RECEPTOR IN THE MIGRATION OF MYOGENIC PRECURSOR CELLS INTO THE LIMB BUD [J].
BLADT, F ;
RIETHMACHER, D ;
ISENMANN, S ;
AGUZZI, A ;
BIRCHMEIER, C .
NATURE, 1995, 376 (6543) :768-771
[5]  
Camp RL, 1999, CANCER, V86, P2259, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO
[6]  
2-2
[7]   The Met receptor degradation pathway -: Requirement for Lys48-linked polyubiquitin independent of proteasome activity [J].
Carter, S ;
Urbé, S ;
Clague, MJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (51) :52835-52839
[8]   Cancer therapy: can the challenge be MET? [J].
Corso, S ;
Comoglio, PM ;
Giordano, S .
TRENDS IN MOLECULAR MEDICINE, 2005, 11 (06) :284-292
[9]   Met, the HGF-SF receptor:: another receptor for Listeria monocytogenes [J].
Cossart, P .
TRENDS IN MICROBIOLOGY, 2001, 9 (03) :105-107
[10]   An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels [J].
Diamonti, AJ ;
Guy, PM ;
Ivanof, C ;
Wong, K ;
Sweeney, C ;
Carraway, KL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (05) :2866-2871